For instance, in the NSCLC cancer PDX models LG1179 (Kras G13R) and LG0551 (squamous cell carcinoma), a single RN765C treatment at 1.5 mg/kg or 3.0 mg/kg, respectively, induces sustained tumor regression, while multiple doses of gemcitabine, carboplatin and paclitaxel either have no effect (carboplatin in LG1179) or only leads to tumor growth inhibition (Figure 5B and 5C). Here, KRAS is linked to neoplasm.